Abstract
Basal insulin peglispro (BIL) comprises insulin lispro covalently bound to a 20-kDa polyethylene glycol (PEG) at lysine B28. The biologic fate of BIL and unconjugated PEG were examined in rats given a single 0.5-mg/kg i.v. or 2-mg/kg s.c. dose of BIL with 14C label in 20-kDa PEG or 125I label in lispro. Unconjugated 14C-labeled 20-kDa PEG was dosed at 10 mg/kg i.v. or s.c. Blood, urine, and feces were collected up to 336 hours after dosing. Radioactivity was measured by scintillation spectrometry, and BIL was quantitated by enzyme-linked immunosorbent assay. Area under the curve and half-life for immunoreactive BIL were lower than those for both 14C and 125I after subcutaneous and intravenous administration. The half-lives of 14C after BIL and PEG dosing were similar. The clearance of immunoreactive BIL was 2.4-fold faster than that of 14C and 1.6-fold faster than 125I. After a subcutaneous dose of BIL, immunoreactive BIL accounted for 31% of the circulating 125I and 16% of the circulating 14C, indicating extensive catabolism of BIL. Subcutaneous bioavailability of BIL was 23%–29%; bioavailability for unconjugated PEG was 78%. For unconjugated PEG, most of the 14C dose was recovered in urine. For BIL, ≥86% of 125I was eliminated in urine and 14C was eliminated about equally in urine and feces. The major 14C-labeled catabolism product of BIL in urine was 20-kDa PEG with lysine attached. The attachment of 20-kDa PEG to lispro in BIL led to a different elimination pathway for PEG compared with unconjugated 20-kDa PEG.
- Copyright © 2015 by The American Society for Pharmacology and Experimental Therapeutics
DMD articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|